AZD-5672

• CAT Number: I003735
• CAS Number: 780750-65-4
• Molecular Formula: C32H38F2N2O5S2
• Molecular Weight: 632.78
• Purity: ≥95%
• Synonyms: N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide
• InChI: InChI=1S/C32H38F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-12,20-22,28,31H,4,13-19H2,1-3H3/t31-/m1/s1
• InChIKey: SCXSQUUTGCWHFU-WJOKGBTCSA-N
• SMILES: CCN(C1CCN(CC1)CCC(C2=CC=C(C=C2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C

AZD-5672 (Cat No.:I003735) is a small-molecule CCR5 antagonist developed by AstraZeneca for research in immunology, inflammation, and infectious diseases. By selectively blocking the CCR5 chemokine receptor, it prevents the binding of natural ligands such as CCL3, CCL4, and CCL5, thereby inhibiting leukocyte trafficking and inflammatory signaling. CCR5 antagonists like AZD-5672 have been investigated for therapeutic potential in HIV infection, autoimmune diseases, and inflammatory disorders. As a research tool, AZD-5672 provides insights into chemokine receptor biology and immune regulation mechanisms.

Reference

[1]. Cumming JG, et al. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1655-9.
[Content Brief]

[2]. Elsby R, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011 Feb;39(2):275-82.
[Content Brief]

[3]. Gerlag DM, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010 Nov;62(11):3154-60.
[Content Brief]